Qishenyiqi dripping pill improves ventricular remodeling and function in patients with chronic heart failure

Chang, Mingzheng; Cheng, Lei; Shen, Yaqian; Zhang, Ying; Zhang, Zhongwen; Hao, Panpan

doi:10.1097/md.0000000000013906

Cited by 18 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(4) Brain Natriuretic Peptide (BNP) . Twenty-one pieces of literature [ 19 – 26 , 30 , 33 , 35 , 36 , 38 – 41 , 43 , 48 , 50 , 54 , 55 ] performed a meta-analysis on BNP, including 12 pieces of low-quality evidence [ 19 – 22 , 24 – 26 , 33 , 35 , 40 , 43 , 50 ], and 9 pieces of very low-quality evidence [ 23 , 30 , 36 , 38 , 39 , 41 , 48 , 54 , 55 ]. The results showed that the difference was statistically significant ( P < 0.05), suggesting that Tongxinluo Capsules, Buyi Qiangxin Tablets, and Yixinshu Capsules combined with CT may significantly reduce BNP in HF patients compared with the control group.…”

Section: Resultsmentioning

confidence: 99%

“…(6) Left Ventricular Ejection Fraction (LVEF) . Thirty-two pieces of literature [ 19 – 25 , 28 – 30 , 33 , 35 – 46 , 48 – 56 ] focused on LVEF, including 6 pieces of moderate-quality evidence [ 30 , 35 , 37 , 51 – 53 ], 19 pieces of low-quality evidence [ 19 – 21 , 23 , 28 , 29 , 33 , 36 , 39 , 41 – 46 , 48 , 49 , 55 , 56 ], and 9 pieces of very low-quality evidence [ 22 , 24 , 25 , 30 , 38 , 40 , 50 , 51 , 54 ]. A meta-analysis [ 54 ] of 818 CHF patients from 8 RCTs showed that no statistically significant differences between Yangxinshi Pills are combined with CT group and CT group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Oral Chinese Patent Medicine Combined with Conventional Therapy for Heart Failure: An Overview of Systematic Reviews

Lin

Liu

Zhang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objectives. By performing an overview of systematic reviews and meta-analyses of the efficacy and safety of oral Chinese patent medicine combined with conventional therapy in the treatment of heart failure, to evaluate the reliability and applicability of the conclusions of the current studies and provide evidence for clinical decision-making. Methods. Systematic reviews and meta-analyses of oral Chinese patent medicine combined with conventional therapy treating heart failure were searched based on standardized search strategy in six electronic databases including PubMed, Embase, Cochrane Library (No. 2 of 2020), China National Knowledge Infrastructure (CNKI), Wanfang Database (Wanfang), and Chinese Scientific Journal Database (VIP) from inception to February 2020. The literature was independently screened and extracted by two researchers. The methodological quality of the included literature was evaluated using the AMSTAR-2 (A Measurement Tool to Assess Systematic Review 2). If necessary, we would summarize the original research data and further perform data synthesis using RevMan software (version 5.3), and the evidence quality of the included literature was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results. A total of 38 systematic reviews and meta-analyses were included, involving 11 kinds of oral Chinese patent medicines, including Qili Qiangxin Capsules (11/38), Qishen Yiqi Dropping Pills (9/38), Shexiang Baoxin Pills (4/38), Wenxin Keli (2/38), Tongxinluo Capsules (2/38), Compound Danshen Dripping Pills (2/38), Zhenyuan Capsules (3/38), Buyi Qiangxin Tablets (2/38), Yangxinshi Tablets (1/38), Xuezhikang (1/38), and Yixinshu Capsules (1/38). The methodological quality of all literature was rated as critically low. The grading of the quality of evidence was 43 moderate, 101 low, and 40 very low. The main reason for the degradation of evidence quality was the risk of bias. In the evaluation of efficacy, there was no statistically significant difference between the two groups in terms of mortality, which is a piece of low-quality evidence. Qili Qiangxin Capsules or Qishen Yiqi Dripping Pills combined with conventional therapy can significantly reduce the hospitalization rate of patients with chronic heart failure, and the quality of the evidence is moderate. The overall efficacy of oral Chinese patent medicine combined with conventional therapy in improving the clinical symptoms, quality of life, exercise endurance, laboratory tests, physical examination, and other indicators of patients with heart failure is confirmed. In the evaluation of safety, there was no significant difference between the two groups. Conclusions. Oral Chinese patent medicine combined with conventional therapy has good clinical efficacy and safety in the treatment of heart failure. However, due to its low level of methodological quality and evidence quality, the current evidence-based conclusions need to be further verified.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Oral Chinese Patent Medicine Combined with Conventional Therapy for Heart Failure: An Overview of Systematic Reviews

Lin

Liu

Zhang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…A lack of consistency across these studies used to be explained by small sample sizes and differences in treatment courses, among other factors. Only one previous meta-analysis has been published in 2019 by Chang et al [ 13 ]. It included 12 high-quality studies (Jadad ≥ 2) involving 942 patients with CHF and suggested that QSYQ is effective and safe for improving ventricular remodeling and heart function in patients, consistent with the results of our study.…”

Section: Discussionmentioning

confidence: 99%

“…However, the results of these studies are not sufficient to establish standards for evidence-based practice, as most are limited by small sample sizes and differences in treatment duration. To the best of our knowledge, only one meta-analysis has evaluated the effects of QSYQ on CHF, including only 12 studies with a Jadad score of ≥2 [ 13 ]. Quality assessment is essential for meta-analyses; however, the Jadad scale is not suitable for study exclusion, as it contains no mention of allocation concealment, which is important in the evaluation of an RCT's internal validity [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies

Wang

Qing

et al. 2020

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Background. Despite evidence for beneficial effects of Qishen Yiqi Drop Pill (QSYQ) on congestive heart failure, the majority of studies are based on insufficient sample sizes. The aim of this study was to evaluate the therapeutic effects of QSYQ using a meta-analysis approach. Methodology/Principal Findings. All relevant studies published before December 31, 2019, were identified by searches of various databases with key search terms. In total, 85 studies involving 8,579 participants were included. The addition of QSYQ to routine Western medicine increased 6-minute walking distance (SMD=2.08, 95% CI: 1.72–2.44, p<0.001), left ventricular ejection fraction (SMD=1.05, 95% CI: 0.87–1.23, p<0.001), and cardiac index (SMD=1.44, 95% CI: 0.92–1.95, p<0.001) and reduced brain natriuretic peptide (SMD=−2.28, 95% CI: -2.81 to -1.76, p<0.001), N-terminal prohormone of brain natriuretic peptide (SMD=−2.49, 95% CI: -3.24 to -1.73, p<0.001), left ventricular end-diastolic dimensions (SMD=−0.92, 95% CI: -1.25 to -0.59, p<0.001), and left ventricular end-systolic dimensions (SMD=−0.55, 95% CI: -0.89 to -0.21, p<0.001). The results were stable in subgroup analyses and sensitivity analyses. Conclusions. Our current meta-analysis indicated that QSYQ combined with Western therapy might be effective in CHF patients. Further researches are needed to identify which subgroups of CHF patients will benefit most and what kind of combination medicines work best.

show abstract

“…QSYQDP is approved by the China State Food and Drug Administration in 2003 for the treatment of cardiovascular disease. Numerous pharmacological studies have revealed the synergistic effect of QSYQDP on cardiovascular diseases ( Chang et al, 2019 ). Recently, QSYQDP (175 mg/kg/day) ( Lu et al, 2015 ) has been shown to alleviate cardiac fibrosis by blocking the activation of RAAS and RAAS activation pathways, particularly by regulating the expression of AT1R and AT2R, and restoring the Ang II-NADPH oxidation-ROS-MMP pathway.…”

Section: Related Research On the Prevention And Treatment Of Myocardi...mentioning

confidence: 99%

Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis

Ren

Zhao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Effective drugs for the treatment of myocardial fibrosis (MF) are lacking. Traditional Chinese medicine (TCM) has garnered increasing attention in recent years for the prevention and treatment of myocardial fibrosis. This Article describes the pathogenesis of myocardial fibrosis from the modern medicine, along with the research progress. Reports suggest that Chinese medicine may play a role in ameliorating myocardial fibrosis through different regulatory mechanisms such as reduction of inflammatory reaction and oxidative stress, inhibition of cardiac fibroblast activation, reduction in extracellular matrix, renin-angiotensin-aldosterone system regulation, transforming growth Factor-β1 (TGF-β1) expression downregulation, TGF-β1/Smad signalling pathway regulation, and microRNA expression regulation. Therefore, traditional Chinese medicine serves as a valuable source of candidate drugs for exploration of the mechanism of occurrence and development, along with clinical prevention and treatment of MF.

show abstract

Qishenyiqi dripping pill improves ventricular remodeling and function in patients with chronic heart failure

Abstract: Supplemental Digital Content is available in the text

Cited by 18 publications

References 7 publications

Efficacy and Safety of Oral Chinese Patent Medicine Combined with Conventional Therapy for Heart Failure: An Overview of Systematic Reviews

Efficacy and Safety of Oral Chinese Patent Medicine Combined with Conventional Therapy for Heart Failure: An Overview of Systematic Reviews

Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies

Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis

Contact Info

Product

Resources

About